Proteome SciencesCHIX:PRML Cash Ratio is 0.05 as of Dec. 2025, which is 62% below its 10-year median of 0.13. The stock has 6 warning signs investors should review. Among 209 Medical Diagnostics & Research companies, Proteome Sciences ranks worse than 92.82% on this metric.
Proteome Sciences has a Cash Ratio of 0.05. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Proteome Sciences's Cash Ratio or its related term are showing as below:
CHIX:PRMl'
s Cash Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.13 Max: 0.32
Current: 0.05
During the past 13 years, Proteome Sciences's highest Cash Ratio was 0.32. The lowest was 0.05. And the median was 0.13.
CHIX:PRMl's Cash Ratio is ranked worse than 92.82% of 209
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.96
vs CHIX:PRMl: 0.05
Proteome Sciences (CHIX:PRMl) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Proteome Sciences Cash Ratio Related Terms
Proteome Sciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for Proteome Sciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:PRML vs TMO, DHR, IDXX: Cash Ratio Comparison
For the Diagnostics & Research subindustry, Proteome Sciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteome Sciences (CHIX:PRML) has a Cash Ratio of 0.05 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Proteome Sciences and its competitors. This is 62% below median its historical median of 0.13. Over the past decade, Proteome Sciences' Cash Ratio has ranged from 0.05 to 0.32. According to the industry distribution chart, Proteome Sciences ranks #194 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 92.8%.
Is Proteome Sciences' Cash Ratio too high?
Proteome Sciences' current Cash Ratio of 0.05 is 62% below median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.32. The Medical Diagnostics & Research industry median Cash Ratio is 0.96. Proteome Sciences' value of 0.05 is 94.8% below this industry median. Based on the distribution chart, Proteome Sciences ranks #194 out of 209 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Proteome Sciences' Cash Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #194 out of 209 companies for Cash Ratio. This places Proteome Sciences in the lower half of its industry. The industry median Cash Ratio is 0.96. Proteome Sciences' value of 0.05 is 94.8% below this benchmark. Historically, Proteome Sciences' own Cash Ratio has ranged from 0.05 to 0.32 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 0.96, Proteome Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.96, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proteome Sciences's current Cash Ratio of 0.05 is 94.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Proteome Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteome Sciences's current Cash Ratio is 0.05, which is 62% below median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Based on GuruFocus' analysis, Proteome Sciences (CHIX:PRML) is currently considered Modestly Undervalued. The stock's GF Value™ is £0.02, compared to a current price of £0.02 — trading 14.5% below its estimated fair value. The current Cash Ratio is 0.05, which is 62% below median its 10-year median of 0.13 and 94.8% below the Medical Diagnostics & Research industry median of 0.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Proteome Sciences (CHIX:PRML), the current Cash Ratio is 0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PRML has been successfully added to your 